Physician profile
Mark W Bonner
NPI 1811961600
$8,784.41
in general payments reported to CMS, 2019-2025
25 companies · $1,673 in 2025
The $1,673 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $748 · 2020: $544 · 2021: $1,209 · 2022: $1,501 · 2023: $1,592 · 2024: $1,518 · 2025: $1,673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,782.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,586.36 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $1,256.69 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,230.46 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $1,138.25 | 2019-2025 | |
| Incyte Corporation | $396.54 | 2023-2025 | Opzelura |
| Amgen INC. | $390.88 | 2020-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $303.98 | 2019-2025 | Tremfya, Simponi, Remicade |
| Sun Pharmaceutical Industries INC. | $246.97 | 2020-2025 | Winlevi |
| Lilly USA, LLC | $224.36 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $192.69 | 2021-2025 | Adbry |
| Ucb, INC. | $163.41 | 2021-2025 | Bimzelx |
| Pfizer INC. | $158.18 | 2019-2025 | |
| Dermavant Sciences, INC. | $126.13 | 2023-2024 | Vtama |
| Organon LLC | $69.52 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $61.88 | 2023-2024 | Zoryve |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $55.21 | 2022-2025 | Sotyktu |
| Organogenesis INC. | $40.97 | 2025 | Puraply Wound Matrix |
| Merck Sharp & Dohme LLC | $29.75 | 2019-2022 | |
| Almirall LLC | $27.01 | 2021-2022 | |
| Biofrontera INC. | $18.86 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Botanix Sb INC | $16.91 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.34 | 2024 | Spevigo |
| Mayne Pharma Commercial LLC | $12.90 | 2021 | |
| Promius Pharma LLC | $10.87 | 2019 | |
| Strata Skin Sciences, INC. | $10.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Bonner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.